Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

Vaccine. 2011 Apr 5;29(16):2836-9. doi: 10.1016/j.vaccine.2011.02.020. Epub 2011 Feb 22.

Abstract

Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200 cells/μL while individuals with CD4 <200 cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients.

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adult
  • Antibodies, Viral / blood
  • CD4 Lymphocyte Count
  • Female
  • HIV / immunology
  • HIV Infections / immunology*
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology*
  • Humans
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza Vaccines / immunology*
  • Influenza, Human / prevention & control*
  • Male
  • Middle Aged
  • Polysorbates / pharmacology
  • Squalene / pharmacology

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Influenza Vaccines
  • MF59 oil emulsion
  • Polysorbates
  • focetria
  • hemagglutinin, human influenza A virus
  • Squalene